Categories: All postsAnalysts

What does RBC think of Evertz Technologies?

RBC Dominion Securities analyst Paul Treiber has initiated coverage of Evertz Technologies (Evertz Technologies Stock Quote, Chart, News, Analysts, Financials TSX:ET) with a “Sector Perform” rating and a $12.00 target price, describing the Burlington, Ont.-based company as “at the forefront of the IP/digital and cloud transition in media.”

In a Sept. 19 report titled ‘Relevant in a Digital World,’ Treiber said Evertz is a global leader in broadcast and media technology, supporting the shift from linear broadcasting to digital through its software-defined video networking, cloud-based software, and 4K/8K ultra-high definition solutions. Customers include Amazon, HBO/WarnerMedia, Disney/ESPN and Google DeepMind.

“Evertz has averaged 30% ROIC over the last 10 years, which reflects well-managed operations (24% Adjusted EBITDA margin average) and prudent capital management. The company has returned the majority of FCF to shareholders through dividends,” he said. “Executives and the board own 64% of shares, ensuring high alignment with shareholders. We forecast Evertz’s ROIC to decline slightly to the high 20% range, but it is still sufficient to fund continued dividend growth.”

At the same time, Treiber pointed to the company’s long-term growth challenges.

“Revenues dropped 21% in FY21, before rebounding 29% in FY22,” he said. “Despite revenue cyclicality, Evertz has averaged 3.9% organic growth over the last 10 years. We believe cyclicality is likely to decline going forward, as reoccurring software and services revenue now accounts for 46% of total revenue as of Q1/FY26. We forecast 4.1% organic growth between FY25 and FY27e.”

Valuation, he added, is expected to remain broadly in line with historical averages.

“Evertz is trading at 14.5 times NTM P/E, which is 18% below peers (18 times) and 1% below its 10-year historical average (14.7 times),” he said. “Evertz has averaged a 5% discount to peers over the last 10 years, given the company’s smaller market cap. We believe Evertz’s valuation fairly values the company’s long-term growth prospects. The stock is trading at a 10.6% FCF yield on our CY26e estimates, which is likely to equate to its dividend yield over time. We believe multiple expansion is likely limited unless organic growth materially accelerates.”

Treiber’s $12.00 price target, below the Street average of $13.56, is based on 14 times his CY26 earnings estimate and assumes the company continues to trade at a discount to peers.

 

-30-

Tagged with: et
Rod Weatherbie

Rod Weatherbie is a journalist based in Prince Edward Island. Since 2004, he has written extensively about the Canadian property and casualty insurance landscape. He was also a founder and contributing editor for a Toronto-based arts website and a PEI-based food magazine. His fiction and poetry have been featured in The Fiddlehead, The Antigonish Review, and Juniper.

Recent Posts

Nvidia is still a cheap stock, this fund manager says

Murray Wealth Group CEO and CIO Bruce Murray says Nvidia (Nvidia Stock Quote, Chart, News, Analysts, Financials NASDAQ:NVDA) remains a… [Read More]

2 minutes ago

Is IC Group Holdings undervaled?

Beacon Securities analyst Gabriel Leung is keeping his eye on IC Group Holdings saying the company offers exposure to consumer… [Read More]

8 minutes ago

Tilray: why this analyst just cut his price target

Haywood Securities analyst Neal Gilmer says lower Canadian cannabis market share is weighing on Tilray Brands (Tilray Brands Stock Quote,… [Read More]

22 hours ago

Why National Bank likes Anaergia right now

National Bank Financial analyst Baltej Sidhu says Anaergia’s (Anaergia Stock Quote, Chart, News, Analysts, Financials TSX:ANRG) divestiture of two legacy… [Read More]

23 hours ago

Canada’s provinces are leading investment boom, RBC says

RBC assistant chief economist Cynthia Leach says the public sector is playing a larger role in Canada’s investment boom than… [Read More]

23 hours ago

Can Eupraxia Pharmaceuticals stock go even higher?

Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong… [Read More]

23 hours ago